PKM and neoplasm: We next sought to evaluate the impact of PKM2 and O-GlcNAc combined with a clinical parameter (invasive tumor size, T stage, or CTS5 that integrates four clinical properties [12]) on the risk of 10-year DFS using multivariate Cox regression analysis.